M. Omaira

Lipedema: A Clinical Challenge-revisited

N. Dimitrov, M. Fankhauser, B. Hrinczenko, 2015 .

Ibrutinib plus fludarabine, cyclophosphamide, and rituximab (iFCR) as initial therapy for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trial

P. Armand, C. Jacobson, Jennifer R. Brown, 2020 .

Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trial.

A. Alencar, A. LaCasce, S. Tyekucheva, 2019, The Lancet. Haematology.

Prognostic implication of GATA3 gene mutation on survival in invasive ductal carcinoma of the breast.

Hardik S. Chhatrala, M. Omaira, K. Kailasam, 2017 .

Longer Term Follow-up of a Multicenter, Phase 2 Study of Ibrutinib Plus Fludarabine, Cyclophosphamide, Rituximab (iFCR) As Initial Therapy for Younger Patients with Chronic Lymphocytic Leukemia

A. Alencar, A. LaCasce, S. Tyekucheva, 2021, Blood.